Member Info for HereforHemo

I would agree that Vlad was concise in all that he said and I took lots of positives from the session. Firstly it is clear that following the feedback from the FDA they are very confident that their primary product candidate HEMO CAR-T will enter clinical trials in 2023. Confident enough to have a new enlarged purpose built laboratory, confident enough to have built clean rooms to manufacture their own CAR, confident enough to have employed a couple of individuals with CAR manufacturing expertise to complement their existing team of excellent scientists and confident enough to work on getting this candidate into clinical trials largely at the exclusion of all other product candidates until proof of concept has been achieved, (Hu-PHEC, CDX, CBR and SAFE HEMO CAR-T) at least that was my take on what was said, not withstanding the fact that CBR or indeed CDX has the potential to be taken further forward by partners in parallel, but it’s clear to me that Hemogenyx have neither the funds nor the resources to progress them on their own. Another major positive to me was the soon to be announced appointment of Professor Koen Van Besien as Medical Director, who will join Hemogenyx in August. His appointment reinforces all the positives I’ve outlined above and is a real coup for Hemogenyx in my opinion, and a sure sign that Hemogenyx scientists have something really special to take forward to the clinic. Also nice to hear the website is finally being updated as we speak, that I know will please some people more than others. To be balanced I would have to say I was disappointed that there would be no PR activity until Hemogenyx had proven themselves in the clinic and especially disappointed at how long the process takes to get into human trials, although I fully understand the reasons why, with the complexities outlined in detail by Vlad. So in summary Hemogenyx is a long term hold from me, with the completion of the Master Cell line for CDX (expected in August) and any partnership announcement on CBR seen very much as a bonus. Still, it’s time to switch off and kick back I think, stick in the bottom draw and see where we are in late December, early January. All being well the war will be over along with the bear market too and as Del Boy would say ‘next year Rodney…’ Good luck to all that decide to hold.

Mr India the simple solution is to sell half your shares to get the cash you need. Hold the other half for six to nine months to recover your losses. That approach would allow you to sit back with a little patience rather than getting depressed watching the SP on a daily basis. Never mind about crashing the SP, one could argue it’s already on the floor. It’ll recover in due course.

It’s obvious why people aren’t buying. Vlad put the CAR-T IND back to later this year and the CDX IND into late next year. They’ll be other updates along the way, especially on CBR but those two are arguably the inflection points. You either wait or you don’t and it appears most don’t want to. Personally I’m not surprised, I’ll wait but a lot have overstretched and can’t wait that long.

HT Whilst we are all frustrated with continued delays it’s important to remember why they have occurred. If you take the CDX antibody, firstly there was a delay of over a year due to Covid, then a further delay whilst Hemogenyx negotiated the IP licensing agreement with Eli Lilly. The positive from this position is that they now own all the IP and you would assume they would not be developing a Master Cell line with Selexis if they didn’t think the product candidate was viable. On CBR, whilst it may just be proven ‘in a dish’ as you eloquently put it, again it’s important to remember that the delay in this case was due to Hemogenyx spending nearly a year compiling a very comprehensive seminal patent application to protect all IP on the approach before progressing. One might argue this was a very sensible approach. They have now allocated funding and in vitro results are imminent. Finally on HEMO CAR-T. Again, it was prudent of Vlad not to commence building the clean room CAR manufacturing facilities until they had the FDA validate their approach. Unfortunately these discussions were put back by the FDA from February until May. The positive is the feedback was very encouraging, Hemogenyx know what is required for IND approval, they have built the clean room required and have employed CAR staff and are employing more as we speak. So in summary whilst the delays are frustrating the bigger picture is that all product candidates ARE progressing to human clinical trials, albeit not as quickly as everyone would like. We just need patience. The candidates are viable and that means in time Hemogenyx will substantially rerate and all will be well for holders. Again Hemogenyx have enough money to achieve proof of concept for at least one product candidate and that alone is massive in this current bear market. Just my take.

JHFH I agree, a MAJOR step forward! Onwards to certification, IND and clinical trials. Pleased you’re finally in Barber as I don’t think it’s getting any cheaper from here, you buy what you can afford. Have a great weekend all, bring on Q3 and Q4. Tick tock.

Dhub I think you know as I do there is very little, if any, risk buying at this price. We’ll done, let’s look forward to that first piece of news!

Marked as a sell..again lol. Don’t be fooled, think they’ve run out of blue pen.

Another 383k added. In for a penny.. :)

Although we don’t know the size of the Hemogenyx clean rooms from what I can see from case studies they shouldn’t take more than two months to build, and I’m assuming they are class 1 facilities. Considering work has already started I can’t see why approvals and IND application wouldn’t be achievable by December. I would also guess the cost per unit wwould be around $30,000 so not overly expensive. So with the master cell line for CDX, in vivo and vitro tests on Covid for CBR, as well as potential partnerships for both CDX and CBR to be announced, I think we have a lot to look forward to over the next six months.

Vlad won’t be coming over for the meeting.

Mr India I agree. I would also note that the so called safe haven of crypto has taken a turn and far more investors are likely to return to small caps. Finally the heads up from the G7 looks as though Ukraine is going to push for a blitz on Russian troops in August, with substantial armoury being delivered to allow them to end the war later this year, and despite what Pumpkin says that May allow a substantial part of the £8bn that investors have withdrawn to come back to the market, just in time for Hemogenyx t become clinical.

I think you are right that a CDX update will be issued soon, maybe sooner than CBR. You are also correct in saying that we are unlikely to hear anything on CAR until the end of the year, unless they announce something pertaining to the clean rooms being fully functional. All in my opinion.

What is critical is getting HEMO CAR-T into clinical trials and that’s exactly what they are doing. However, that doesn’t mean an announcement on a partnership on CBR would not be welcome. I’ve registered so I’ll see you there. Could be an interesting couple of weeks.

I notice the normal suspects are coming out of the woodwork and being critical of those who voice an opinion or even be brave enough to give their thoughts on a prediction for the share price. And yes, you can go back many months and I’d hazard a guess that everyone has been wrong on numerous occasions. However, people post on the information as it stands or more importantly as it stood. Nobody could predict the FDA PIND submitted last December would be delayed until May. Nobody could predict the global economy would crash due to the Russian invasion of Ukraine and nobody thought that when Hemogenyx moved into their purpose built laboratory that the clean rooms required for the manufacture of CAR would still need to be built. **** happens, live with it. It’s the Pharmaceutical sector, delays happen. No point having a dig at people for voicing an opinion. You don’t have to read them and you don’t have to believe them. Do your own research. Make your own decisions and take responsibility for your own investments.

I think my biggest disappointment following the interview has been the confirmation that Hu-PHEC has been shelved and that CDX has been substantially delayed, but we have to understand the reasons why. Firstly, although fully funded for the next year, Hemogenyx haven’t got enough money to progress all of their product candidates to where they want them to be, so they have prioritised. In essence they are very much victims of their own success. They have decided, and rightly so in my opinion, the vast majority of their funds will go towards achieving proof of concept with HEMO CAR-T. Whilst there has been a further delay it’s important to recognise it’s a logistical delay as opposed to scientific. Hemogenyx have chosen to build and install their own clean rooms to manufacture their own CAR, and adopting this strategy has undoubtedly put the timeline back. BUT, there are positives from this approach. Firstly, do you think Hemogenyx would be building their own manufacturing capability if they didn’t think HEMO CAR-T would get into and through clinical trials? Do you think Hemogenyx would be employing senior scientists with CAR-T expertise to oversee the development, management and production of CAR-T (and do you think these individuals would be keen to join Hemogenyx) if they all didn’t think this candidate would work and save lives? So yes there is a delay, but a planned one. A decision made to save Hemogenyx money over the long term, around £12m to be precise, from the costs of doing things yourself rather than outsourcing. But remember there’s also money allocated to another candidate, or platform to be precise, CBR. Money that will get CBR to where Hemogenyx want it to be, to work on an actual live virus. The first chosen virus I understand is Covid and all variants associated with it. This work is ongoing and in my opinion will be the next announcement we get from Hemogenyx.
So timeline as I see it. CBR proof of concept Q3, CAR-T IND Q4/Q1, next year CAR-T clinical trials Q1/Q2, CDX IND Q3, CDX clinical trials Q3/Q4. It’s also highly possible various partnerships and licensing agreements may be announced throughout the journey as well. So, just my thoughts but plenty to look forward to in my opinion, albeit frustrating at the moment.

Very informative as always JHFH. Many thanks.

Doubt if questions unrelated to the AGM will be answered. I’ll save my questions for the next Zoom session with Vlad

Whilst both Bauer and Auringer are greedy bastards in the extreme it is worth pointing out that their £60m fraud of private investors was only for companies listed in the United States and therefore has had no impact on Hemogenyx, a UK listed company. That being said, the sudden spike to 15p with an equally dramatic fall (I think a 44% spread on the day IDX memory serves) seems more than a coincidence. As major holders at the time they certainly had the opportunity. Personally I’m pleased they are no longer involved in Hemogenyx and even more pleased they’ll face 20 years in jail for each offense. Whether they screwed us Hemogenyx investors or not, I hope they die in jail. Absolute scum. Thankfully Hemogenyx survived and we move on from a position of strength and financial security.

People starting to load up. Major buy of 202 shares. News coming? :)

Thanks for that Chris. I’m pretty sure that the bear market would have ended earlier this year were it not for Ukraine. However the key thing is having money in the bank. HEMO being fully funded for another 12 months coupled with major progress on CAR-T (which will undoubtedly move into human clinical trials in my opinion),CDX and CBR, make Hemogenyx one of the safest small cap investments in the market. A very exciting few days weeks and months ahead.